Analysts View Astellas’ Pick Of Former Pfizer Exec To Head Global Development As Nod To Daiichi Sankyo's Success
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas Pharma's decision to move its global development headquarters to Illinois may be a reflection of how other major Japanese pharmas see Daiichi Sankyo's position in the market, a Japanese analyst says
You may also be interested in...
Japanese Takeda Buys Abbott’s Stake In TAP Joint U.S. Venture
Japanese drug maker Takeda will establish Takeda America Holdings after finalizing a deal March 19 to obtain a 100 percent stake in TAP Pharmaceutical Products, its 50/50 joint venture with Abbott
Japanese Takeda Buys Abbott’s Stake In TAP Joint U.S. Venture
Japanese drug maker Takeda will establish Takeda America Holdings after finalizing a deal March 19 to obtain a 100 percent stake in TAP Pharmaceutical Products, its 50/50 joint venture with Abbott
Daiichi Sankyo Remains Bullish On Prasugrel, Rivoglitazone Despite Safety Concerns – R&D Day
TOKYO - Daiichi Sankyo provided a status report to investors during a Feb. 21 research and development update in Tokyo. In particular, company officials responded to investor safety concerns related to two key pipeline drugs - anti-platelet drug prasugrel (CS-747) and rivoglitazone (CS-011), a PPAR agonist for type 2 diabetes